Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): A randomised, multicentre, open-label, phase 3 trial

The Lancet Oncology

Volumn 15, Issue 4, 2014, Pages 396-405

  Pignata, Sandro ^a   Scambia, Giovanni ^b   Katsaros, Dionyssios ^c   Gallo, Ciro ^d   Pujade Lauraine, Eric ^e   De Placido, Sabino ^f   Bologna, Alessandra ^g   Weber, Beatrice ^h   Raspagliesi, Francesco ⁱ   Panici, Pierluigi Benedetti ^j   Cormio, Gennaro ^k   Sorio, Roberto ^l   Cavazzini, Maria Giovanna ^m   Ferrandina, Gabriella ⁿ   Breda, Enrico ^o   Murgia, Viviana ^p   Sacco, Cosimo ^q   Cinieri, Saverio ^r   Salutari, Vanda ^b   Ricci, Caterina ^b   Pisano, Carmela ^a   Greggi, Stefano ^a   Lauria, Rossella ^f   Lorusso, Domenica ⁱ   Marchetti, Claudia ^a   Selvaggi, Luigi ^k   Signoriello, Simona ^d   Piccirillo, Maria Carmela ^a   Di Maio, Massimo ^a   Perrone, Francesco ^a   more..

^a NATIONAL CANCER INSTITUTE   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

^c UNIVERSITY OF TURIN   (Italy)

^d SECOND UNIVERSITY OF NAPLES   (Italy)

^e HÔTEL DIEU   (France)

^f UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^g S MARIA NUOVA HOSPITAL   (Italy)

^h CENTRE ALEXIS VAUTRIN   (France)

ⁱ NATIONAL CANCER INSTITUTE   (Italy)

^j SAPIENZA UNIVERSITY OF ROME   (Italy)

^k POLICLINICO   (Italy)

^l CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^m Oncologia ed Ematologia AO Carlo Poma   (Italy)

ⁿ CATHOLIC UNIVERSITY   (Italy)

^o SAN GIOVANNI CALIBITA FATEBENEFRATELLI HOSPITAL   (Italy)

^p SANTA CHIARA HOSPITAL   (Italy)

^q SANTA MARIA DELLA MISERICORDIA UNIVERSITY HOSPITAL   (Italy)

^r EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; PACLITAXEL;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ALLERGY; ANEMIA; ANOREXIA; ARTICLE; BLEEDING; CANCER SURVIVAL; CARDIOTOXICITY; CONSTIPATION; CONTROLLED STUDY; DEHYDRATION; DOSAGE SCHEDULE COMPARISON; DRUG EFFICACY; DRUG FATALITY; DRUG RESPONSE; DRUG SAFETY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; FOLLOW UP; FRANCE; HAIR LOSS; HEART ARRHYTHMIA; HUMAN; INFECTION; INTESTINE PERFORATION; ITALY; KIDNEY FAILURE; LEUKOPENIA; LIVER TOXICITY; LUNG TOXICITY; MAJOR CLINICAL STUDY; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEPHROTOXICITY; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; OVARY CANCER; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SKIN TOXICITY; THROMBOCYTOPENIA; TREATMENT OUTCOME; VERY ELDERLY; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; FRANCE; HUMANS; ITALY; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; NEOPLASM STAGING; OVARIAN NEOPLASMS; PACLITAXEL; PROPORTIONAL HAZARDS MODELS; QUALITY OF LIFE; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84897422241     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(14)70049-X     Document Type: Article

References (33)

1. Thigpen T, duBois A, McAlpine J, et al. First-line therapy in ovarian cancer trials. Int J Gynecol Cancer 2011, 21:756-762. the Gynecologic Cancer InterGroup.
2. Saito K, Kikuchi Y, Fujii K, Kita T, Furuya K Effect of paclitaxel on vascular endothelial growth factor (VEGF) and interleukin (IL)-8 in serum of patients with recurrent ovarian cancer: a comparison of weekly vs triweekly regimens. Target Oncol 2006, 1:86-89.
3. Fennelly D, Aghajanian C, Shapiro F, et al. Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer. J Clin Oncol 1997, 15:187-192.
4. 2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: a Gynecologic Oncology Group study. Gynecol Oncol 2006, 101:436-440. the Gynecologic Oncology Group.
5. Klaassen U, Wilke H, Strumberg D, Eberhardt W, Korn M, Seeber S Phase I study with a weekly 1 h infusion of paclitaxel in heavily pretreated patients with metastatic breast and ovarian cancer. Eur J Cancer 1996, 32A:547-549.
6. Markman M, Hall J, Spitz D, et al. Phase II trial of weekly single-agent paclitaxel in platinum/paclitaxel-refractory ovarian cancer. J Clin Oncol 2002, 20:2365-2369.
7. Kikuchi A, Sakamoto H, Yamamoto T Weekly carboplatin and paclitaxel is safe, active, and well tolerated in recurrent ovarian cancer cases of Japanese women previously treated with cisplatin-containing multidrug chemotherapy. Int J Gynecol Cancer 2005, 15:45-49.
8. Rose PG, Smrekar M, Fusco N A phase II trial of weekly paclitaxel and every 3 weeks of carboplatin in potentially platinum-sensitive ovarian and peritoneal carcinoma. Gynecol Oncol 2005, 96:296-300.
9. Sehouli J, Stengel D, Mustea A, et al. Weekly paclitaxel and carboplatin (PC-W) for patients with primary advanced ovarian cancer: results of a multicenter phase-II study of the NOGGO. Cancer Chemother Pharmacol 2008, 61:243-250. the Ovarian Cancer Study Group of the Nord-Ostdeutsche Gesellschaft für Gynäkologische Onkologie.
10. van der Burg MEL, Boere IA, Berns PMJJ Dose-dense therapy is of benefit in primary treatment of ovarian cancer: contra. Ann Oncol 2011, 22(suppl 8):viii33-viii39.
11. Watanabe Y, Nakai H, Ueda H, Hoshiai H Evaluation of weekly low-dose paclitaxel and carboplatin treatment for patients with platinum-sensitive relapsed ovarian cancer. Gynecol Oncol 2005, 96:323-329.
12. Basen-Engquist K, Bodurka-Bevers D, Fitzgerald MA, et al. Reliability and validity of the functional assessment of cancer therapy-ovarian. J Clin Oncol 2001, 19:1809-1817.
13. Huang HQ, Brady MF, Cella D, Fleming G Validation and reduction of FACT/GOG-Ntx subscale for platinum/paclitaxel-induced neurologic symptoms: a gynecologic oncology group study. Int J Gynecol Cancer 2007, 17:387-393.
14. Katsumata N, Yasuda M, Takahashi F, et al. Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet 2009, 374:1331-1338. for the Japanese Gynecologic Oncology Group.
15. Schemper M, Smith TL A note on quantifying follow-up in studies of failure time. Control Clin Trials 1996, 17:343-346.
16. Pinheiro JC, Bates DM Mixed-effects models in S and S-Plus 2000, Springer, New York.
17. Colombo N, Peiretti M, Garbi A, Carinelli S, Marini C, Sessa C Non-epithelial ovarian cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012, 23(suppl 7):vii20-vii26. the ESMO Guidelines Working Group.
18. du Bois A, Lück HJ, Meier W, et al. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst 2003, 95:1320-1329. the Arbeitsgemeinschaft Gynäkologische Onkologie Ovarian Cancer Study Group.
19. Neijt JP, Engelholm SA, Tuxen MK, et al. Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer. J Clin Oncol 2000, 18:3084-3092.
20. Ozols RF, Bundy BN, Greer BE, et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 2003, 21:3194-3200. the Gynecologic Oncology Group.
21. Pignata S, Scambia G, Ferrandina G, et al. Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: the MITO-2 randomized phase III trial. J Clin Oncol 2011, 29:3628-3635.
22. Vasey PA, Jayson GC, Gordon A, et al. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. J Natl Cancer Inst 2004, 96:1682-1691. the Scottish Gynaecological Cancer Trials Group.
23. Bookman MA, Brady MF, McGuire WP, et al. Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup. J Clin Oncol 2009, 27:1419-1425.
24. Armstrong DK, Bundy B, Wenzel L, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 2006, 354:34-43. the Gynecologic Oncology Group.
25. Burger RA, Brady MF, Bookman MA, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 2011, 365:2473-2483. the Gynecologic Oncology Group.
26. Perren TJ, Swart AM, Pfisterer J, et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 2011, 365:2484-2496. the ICON7 Investigators.
27. Katsumata N, Yasuda M, Isonishi S, et al. Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial. Lancet Oncol 2013, 14:1020-1026. the Japanese Gynecologic Oncology Group.
28. Harano K, Terauchi F, Katsumata N, et al. Quality-of-life outcomes from a randomized phase III trial of dose-dense weekly paclitaxel and carboplatin compared with conventional paclitaxel and carboplatin as a first-line treatment for stage II-IV ovarian cancer: Japanese Gynecologic Oncology Group Trial (JGOG3016). Ann Oncol 2014, 25:251-257.
29. Ma BBY, Hui EP, Mok TSK Population-based differences in treatment outcome following anticancer drug therapies. Lancet Oncol 2010, 11:75-84.
30. Gonzalez-Martin A, Gladieff L, Tholander B, et al. Efficacy and safety results from OCTAVIA, a single-arm phase II study evaluating front-line bevacizumab, carboplatin and weekly paclitaxel for ovarian cancer. Eur J Cancer 2013, 49:3831-3838. the OCTAVIA Investigators.
31. Bolis G, Scarfone G, Polverino G, et al. Paclitaxel 175 or 225 mg per meters squared with carboplatin in advanced ovarian cancer: a randomized trial. J Clin Oncol 2004, 22:686-690.
32. Chan J, Brady M, Penson R, et al. Phase III trial of every-3-weeks paclitaxel vs. dose dense weekly paclitaxel with carboplatin +/- bevacizumab in epithelial ovarian, peritoneal, fallopian tube cancer: GOG 262 (NCT01167712). Int J Gynecol Cancer 2013, 23(suppl 1):9.
33. Xiong X, Sui M, Fan W, Kraft AS Cell cycle dependent antagonistic interactions between paclitaxel and carboplatin in combination therapy. Cancer Biol Ther 2007, 6:1067-1073.